Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
The latest announcement is out from Aroa Biosurgery Ltd ( (AU:ARX) ).
Aroa Biosurgery Limited announced an upcoming webinar to discuss its Full Year 2025 Financial Results, which will now be released on May 29, 2025, instead of the previously scheduled May 27. This update reflects the company’s commitment to transparency and engagement with investors and stakeholders, potentially impacting its market positioning and investor relations.
The most recent analyst rating on (AU:ARX) stock is a Buy with a A$1.05 price target. To see the full list of analyst forecasts on Aroa Biosurgery Ltd stock, see the AU:ARX Stock Forecast page.
More about Aroa Biosurgery Ltd
Aroa Biosurgery is a soft-tissue regeneration company that develops, manufactures, sells, and distributes medical and surgical products aimed at improving healing in complex wounds and soft tissue reconstruction. The company’s products are based on a proprietary AROA ECM™ technology platform, utilizing a novel extracellular matrix biomaterial derived from sheep forestomach. Aroa Biosurgery is headquartered in Auckland, New Zealand, and is listed on the Australian Securities Exchange.
Average Trading Volume: 316,325
Technical Sentiment Signal: Sell
Current Market Cap: A$158.7M
Learn more about ARX stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue